ARCA biopharma, Inc.
Hedge Funds Holdings
Last updated:
ARCA biopharma, Inc.‘s stocks are currently a part of 15 hedge funds’ portfolios, which represents 8.06% of the total amount of its stocks outstanding. This makes up a total of 1.16M shares of ARCA biopharma, Inc.. Compared to the previous quarter, the number fell by -55.56% or -1.45M shares fewer. As for the holding position changes, 33.33% (5) of current hedge fund investors increased the number of shares held, 13.33% (2) of current holders sold a part of the shares held. 4 hedge funds are new holders of ARCA biopharma, Inc. stock in Q1 2023, it is 26.67% of total holders.
Hedge funds holding ARCA biopharma (Q2 2018 – Q1 2023)
| Q2 2018 | 13 |
|---|---|
| Q3 2018 | 10 |
| Q4 2018 | 10 |
| Q1 2019 | 11 |
| Q2 2019 | 8 |
| Q3 2019 | 7 |
| Q4 2019 | 7 |
| Q1 2020 | 5 |
| Q2 2020 | 3 |
| Q3 2020 | 9 |
| Q4 2020 | 15 |
| Q1 2021 | 14 |
| Q2 2021 | 12 |
| Q3 2021 | 15 |
| Q4 2021 | 15 |
| Q1 2022 | 18 |
| Q2 2022 | 20 |
| Q3 2022 | 21 |
| Q4 2022 | 20 |
| Q1 2023 | 15 |
Hedge funds changes in ARCA biopharma positions (Q2 2018 – Q1 2023)
| Q2 2018 | 4 | 1 | 2 | 4 | 2 |
|---|---|---|---|---|---|
| Q3 2018 | 0 | 4 | 1 | 3 | 2 |
| Q4 2018 | 1 | 2 | 2 | 1 | 4 |
| Q1 2019 | 3 | 2 | 1 | 2 | 3 |
| Q2 2019 | 8 | 0 | 0 | 11 | -11 |
| Q3 2019 | 2 | 1 | 1 | 3 | 0 |
| Q4 2019 | 3 | 1 | 0 | 3 | 0 |
| Q1 2020 | 1 | 2 | 1 | 3 | -2 |
| Q2 2020 | 0 | 0 | 3 | 2 | -2 |
| Q3 2020 | 7 | 0 | 1 | 1 | 0 |
| Q4 2020 | 10 | 3 | 0 | 4 | -2 |
| Q1 2021 | 4 | 6 | 2 | 5 | -3 |
| Q2 2021 | 4 | 4 | 2 | 6 | -4 |
| Q3 2021 | 6 | 5 | 2 | 3 | -1 |
| Q4 2021 | 3 | 4 | 3 | 3 | 2 |
| Q1 2022 | 5 | 4 | 4 | 2 | 3 |
| Q2 2022 | 7 | 5 | 3 | 5 | 0 |
| Q3 2022 | 4 | 5 | 5 | 3 | 4 |
| Q4 2022 | 5 | 6 | 3 | 6 | 0 |
| Q1 2023 | 4 | 5 | 2 | 0 | 4 |
Hedge funds changes in ARCA biopharma stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 23,000 | 50,000 |
| Q1 2021 | 271,000 | 140,000 |
| Q2 2021 | 27,000 | 331,000 |
| Q3 2021 | 18,000 | 419,000 |
| Q4 2021 | 169,000 | 147,000 |
| Q1 2022 | 223,000 | 141,000 |
| Q2 2022 | 328,000 | 3,957,000 |
| Q3 2022 | 196,000 | 3,124,000 |
| Q4 2022 | 165,200 | 130,788 |
| Q1 2023 | 30,000 | 45,784,000 |